To develop a comprehensive computational framework to simulate tissue distribution of gold nanoparticles (AuNP) across several species. Materials & methods: This framework was built on physiologically based pharmacokinetic modeling, calibrated and evaluated with multiple independent datasets. Results: Rats and pigs seem to be more appropriate models than mice in animal-to-human extrapolation of AuNP pharmacokinetics and that the dose and age should be considered. Incorporation of in vitro and/or in vivo cellular uptake and toxicity data into the model improved toxicity assessment of AuNP. Conclusion: These results partially explain the current low translation rate of nanotechnology-based drug delivery systems from mice to humans. This simulation approach may be applied to other nanomaterials and provides guidance to design future translational studies. Numerous studies showed that exposure to some nanoparticles (NP) may be toxic to organisms [1] [2] [3] [4] . Available in vitro and in vivo cellular uptake, pharmacokinetic and toxicity studies have different experimental designs that preclude comparing and combining results to gain deep insights into NP interspecies pharmacokinetics and risk assessment [5] [6] [7] [8] . Therefore, it is crucial to have a meta-analysis method that can integrate available experimental and theoretical studies to systemically assess both NP pharmacokinetics and cellular toxicity across species, as well as to make in vitro to in vivo extrapolations (IVIVE) [8] [9] [10] [11] [12] .
Numerous studies showed that exposure to some nanoparticles (NP) may be toxic to organisms [1] [2] [3] [4] . Available in vitro and in vivo cellular uptake, pharmacokinetic and toxicity studies have different experimental designs that preclude comparing and combining results to gain deep insights into NP interspecies pharmacokinetics and risk assessment [5] [6] [7] [8] . Therefore, it is crucial to have a meta-analysis method that can integrate available experimental and theoretical studies to systemically assess both NP pharmacokinetics and cellular toxicity across species, as well as to make in vitro to in vivo extrapolations (IVIVE) [8] [9] [10] [11] [12] .
Compared with observational methods that are expensive and time-consuming, computational methods can offer a good adjunct to, or once validated, potentially substitute for predicting NP dosimetry and toxicity [12] [13] [14] [15] . Both classical quantitative structure-activity/toxicity relationship (QSAR/ QSTR) models [16, 17] and advanced QSAR/ QSTR perturbation models [18, 19] have been successfully developed to predict cytotoxicity, ecotoxicity or antibacterial activity of many different NP under multiple experimental conditions (i.e., different cell types, exposure times, measurement methods, sizes, shapes and chemical compositions of NP). While QSAR/QSTR models are a useful in silico tool to predict toxic effects of chemicals or NP against diverse biosystems [16] [17] [18] [19] , they cannot be used to conduct interspecies extrapolation or IVIVE of target tissue dosimetry and toxicity.
Physiologically based pharmacokinetic (PBPK) modeling is one computational approach that simulates the absorption, distribution, metabolism and elimination (ADME) of chemicals and/or NP in the body using mathematical equations. Well- 1 validated PBPK models may be used to conduct IVIVE and interspecies extrapolation of NP tissue dosimetry and toxicity [11, 12] . Many investigators have tried to develop PBPK models for NP in rodents [20] [21] [22] [23] , but none of the available models are comprehensive enough to conduct IVIVE and interspecies extrapolation.
Recently, we have developed a PBPK model for gold nanoparticles (AuNP) in mice [23] . AuNP were selected as model NP because they are used widely in nanomedicine [24] and there are sufficient pharmacokinetic and toxicity data for developing a well-validated model [2, 5, 23] . Based upon this mouse model [23] , the objective of this study was to create a comprehensive computational framework that could simulate the tissue distribution of AuNP across several species, as well as incorporate in vitro and in vivo cellular uptake and toxicity data to inform pharmacokinetics, exposure and toxicity assessment. Therefore, we optimized and extended the mouse model to simulate the kinetics of AuNP in rats and pigs. The rat and pig models were evaluated with independent datasets to ensure the validity of the model. Then, the rodent and porcine models from various exposure scenarios were independently scaled to humans to determine the optimum model for animal-to-human extrapolation of NP pharmacokinetics (Figure 1 ). The derived optimal human model was then used as a framework for incorporating in vitro and in vivo toxicity data to predict the associated human equivalent doses for risk assessment.
Materials & methods

Data source & model structure
The data for rat and pig PBPK model calibration were obtained from the published literature [25] [26] [27] . As detailed in Supplementary Table 1 , this model is primarily for AuNP coated with polyethylene glycol (PEG), gum arabic or citrate, and only pharmacokinetic data for these types of AuNP with at least four measurement time points were selected for model calibration. The model structure was based on our mouse PBPK model with minor modifications [23] . Briefly, it consisted of seven compartments: plasma (or blood), liver, spleen, kidneys, lungs, brain and rest of body (Figure 1 ). The same methods [23] describing transcapillary membrane transport with a membrane-limited approach, uneven distribution between plasma and tissue using the term 'distribution coefficient' and endocytosis with the Hill function, as well as biliary and urinary excretion using a first-order equation were applied in the present model. Dissolution of AuNP was not considered due to lack of experimental evidence [5] . To simplify the model and increase its harmonization, a general approach describing endocytosis of AuNP from blood to tissue phagocytic cells was used across all species (Figure 1) . In order to simulate dose dependency, the term maximum uptake capacity for each tissue (except the brain) was included. AcslX version 3.0.2.1 (Aegis Technologies Group, Inc., AL, USA) was used to run all simulations. Model code in continuous simulation language (CSL) format is provided in the Supplementary Information as well as our website [28] .
Model parameterization
Physiological parameters for mice, rats, pigs and humans are provided in Supplementary Table 2 [25, 26, [29] [30] [31] [32] [33] [34] [35] . NP-specific parameters used in the mouse PBPK model [23] , such as distribution coefficients and permeability coefficients, were kept the same in the present model. This creates the most parsimonious model by using a minimum number of estimated parameters and applying a generic value for parameters across species. Endocytic parameters for each type of AuNP (application size domain: 13-100 nm) in each species had to be re-estimated by using the same approach used in the mouse model [23] because uptake of NP depends on the size, dose, surface coating, cell type and species [6] . The urine elimination rate in the pig model was estimated by visually fitting to the urine data in the pig study [25] ; this optimized parameter value was used in the rat and human models. All NP-specific parameters are provided in Supplementary Table 3 .
Model evaluation
The overall goodness of fit between simulated and experimental data was evaluated with linear regression analysis using GraphPad Prism 6 (GraphPad Software Inc., CA, USA). The predictive ability of the rat and pig models was evaluated with other studies where similar types and doses of AuNP were used (Supplementary Table 1 ) [36, 37] . The criterion of a validated model was based on WHO guidelines, namely, a model is considered reasonable if simulation results are within a factor of two of independent experimental data [38] . Sensitivity and uncertainty analyses have been conducted and reported in the mouse model [23] and, therefore, were not repeated in this study.
Model cross-species extrapolation
Model extrapolation from mice, rats and pigs to humans was conducted by changing physiological parameters to be human-specific and keeping NPspecific parameters the same as in the original animal models. The derived human models were then used to predict the blood kinetics of a nanomedicine CYT-6091, a rhTNF-bound PEG-coated 27-nm AuNP, after intravenous (iv.) injection in advanced- iv.: Intravenous.
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future science group stage cancer patients [39] . Besides direct model extrapolation from laboratory animals to humans, a revised approach based on the relative density of phagocytic cells in the liver of juvenile pigs compared with adult humans was tested. Briefly, based on the evidence that the density of Kupffer cells in juvenile pigs is around sevenfold (0.89 × 10 6 vs 0.13 × 10 6 cells/g liver tissue) higher than in adult humans [40, 41] , in addition to changing physiological parameters to be human-specific, the juvenile pig model was scaled to humans by decreasing the maximum endocytic rates and capacities by sevenfold. Simulations using human models derived from different approaches (mouse model, medium-dose rat model, low-dose rat model, original pig model and revised pig model) were compared with experimental data [39] to determine the optimal human model.
Model application
To show model application in exposure and risk assessment, the optimal human model was used to predict blood and liver Au concentrations after iv. injection with AuNP across a wide dose range (0.001-100 mg/kg). This dose range was selected based on the doses used in the laboratory animals [2, 5] . The liver was selected as the target organ because AuNP predominantly accumulate in the liver after exposure regardless of exposure route, dose, size and species [5, 42] . To assess the risk of AuNP exposure, a literature review on the in vitro and in vivo toxicity of AuNP was carried out and representative results are provided in Supplementary Table 4 . Next, the human equivalent doses associated with representative in vitro cytotoxic concentrations of AuNP in primary human tissue [43] and blood cells [44] , as well as the reported in vivo toxic dose in rats [26] , were predicted by using the human PBPK model based on the IVIVE and species extrapolation methods [45] . Specifically, the human equivalent doses were the doses when simulated maximum liver Au concentrations were equal to the reported in vitro cytotoxic nominal concentrations or the doses resulting in identical maximum liver Au concentrations in rats where adverse effects were observed.
Results
Model development in rats & pigs
Our mouse PBPK model [23] was scaled to rats and pigs (Figure 1 ) by using species-specific physiological and endocytic parameters (Supplementary Tables 2 & 3) . Model simulation results were well correlated to the observed concentrations or amounts of Au in the blood, liver, spleen, kidneys, lungs and/or urine of rats [27] and pigs [25] after iv. exposure to 0.8 and 2.0 mg/kg AuNP, respectively ( Figure 2 ). The determination coefficients (R 2 ) between simulated and measured data were 0.98 for both models. These results suggest that the rat and pig PBPK models at doses from 0.8 to 2.0 mg/kg have been calibrated properly.
Evaluation of the rat & pig models
The predictive capability of the rat and pig models was then evaluated with independent datasets [36, 37] (Supplementary Table 1 ). Both models adequately simulated the observed liver and spleen concentrations of Au, differing less than twofold (Supplementary Figure 1) , which is considered 'validated' according to the WHO PBPK model evaluation criterion [38] . These results suggest that both the rat and pig models have excellent predictive capability of the tissue distribution of AuNP.
Model extrapolation from medium to low doses
Since the doses used in the animal studies were generally higher than the actual doses that humans are exposed to and NP pharmacokinetics is dose dependent, it is critical to have a low-dose model [5, 39] . Therefore, the rat model for medium doses (∼1.0 and ∼0.01 mg/kg were defined as medium and low doses, respectively) was extrapolated to simulate low-dose kinetics of AuNP [26] using low-dose-specific endocytic parameters (Supplementary Table 3 ). Simulation results matched the observed Au concentrations [26] in blood, liver, spleen, kidneys and lungs of rats after low-dose iv. administration (R 2 = 0.98; Supplementary Figure 2) , suggesting that the low-dose model was calibrated properly.
Model application: predictions of dosedependent tissue distribution
To reveal NP dose-dependent kinetics, we employed the medium-dose and low-dose rat models to predict percentage tissue distribution of the injected dose (%ID). The results showed that both absolute (%ID) and relative (%ID/g tissue) distributions primarily to phagocytic organs (e.g., liver, spleen and lungs) were consistently several fold higher in the medium-dose than in the lowdose groups (Figure 3) . Next, we compared the simulated endocytic rates in liver and spleen of rats after iv. injection with the same dose of AuNP (0.01 mg/kg) using both the models. We noticed that the low-dose modelpredicted liver and spleen endocytic rates were approximately four-to fivefold lower than the predicted rates by the medium-dose model (Supplementary Figure 3) . These data suggest that, besides surface coatings and sizes [6] , endocytosis of AuNP is highly dependent on the dose and it may be a key contributing factor to their 10 .2217/nnm.15.177 www.futuremedicine.com Evaluation of model extrapolation from mice, rats or pigs to humans
To assess which of the studied PBPK models can be extrapolated successfully to humans, we scaled the rodent and porcine models to humans by using the human-specific physiological parameter (e.g., blood flow) and keeping the endocytic parameters the same as those in each respective animal model (Figure 1 ). The derived human models were employed to simulate blood concentrations of AuNP-based nanomedicine (CYT-6091) in humans [39] . As shown in Figures 1 and 4 , the human models derived from the mouse model, mediumdose rat model or original pig model failed to capture the blood kinetic profiles (R 2 < 0.87), but the human models derived from the low-dose rat model and the revised pig model properly simulated the measured blood levels of AuNP, with the R 2 values being 0.9427 and 0.9368, respectively. Based on the R 2 value, the human model derived from the low-dose rat model was selected as the optimal human model for subsequent analyses.
Discussion
The pharmacokinetics and safety of NP are routinely evaluated in laboratory animals prior to applications in humans. Thus, it is crucial to understand interspecies difference in NP pharmacokinetics before we confidently use data generated in laboratory animal species to make inferences in humans. The present study successfully established a comprehensive computational framework that properly simulated tissue distribution of AuNP across several species. One of the most important findings is that rats and pigs appear to be more appropriate model species than mice in animal-to-human extrapolation of NP pharmacokinetics and the dose and age should be considered for this extrapolation. This computational comparative analysis of NP pharmacokinetics is novel in the field of nanotechnology.
The key finding that rats and pigs seem to be more suitable models than mice may be a function of different surface coatings, sizes, doses, ages and/or species/strain/breed among the different studies used in model calibration and evaluation [23, [25] [26] [27] 39] . The explanation of surface coatings is unlikely because the mouse and human studies both used PEG-coated AuNP [23, 39] , a coating that minimizes species differences in protein corona effects [5] [6] 9] that would be expected for NP of different coatings that facilitate protein adsorption. In addition, the particle size difference is less likely to be of concern because the sizes used in the mouse, rat, pig and human studies were Interspecies physiologically based pharmacokinetic modeling of gold nanoparticles Research Article quite close (13-27 nm) [23, [25] [26] [27] 39] . The fact that the doses (0.001286-0.01726 mg/kg) used in the human study [39] are close to the low-dose rat study [26] , but far lower than the medium-dose rat study [27] , suggests that dose-dependent disposition is the likely factor. A second possible reason is the difference in the relative density of phagocytic cells in major organs between juvenile pigs and adult humans [40, 41] . Therefore, we revised the original pig-model-derived human model based on the relative density of Kupffer cells in juvenile pigs and adult humans [40, 41] . Simulation results from the revised pig-model-derived human model were well correlated with the observed human data (Figure 4) . These results suggest that extrapolations of NP pharmacokinetics from rats or pigs to humans are plausible provided that the species-specific model parameters are adjusted appropriately. The fact that the present models converged does imply that it is possible to conduct interspecies extrapolations for such covered particles. However, whether this conclusion applies to AuNP with other surface functionalizations remains to be investigated.
The reason that rats and pigs may be more suitable models than mice in extrapolating NP pharmacokinetics to humans is multifaceted. Anatomically, the mouse and pig spleen capillaries are nonsinusoidal with predominant blood flow through the open-circulation route where NP filtration is mainly regulated by barrier cells; but the spleen capillaries in rats and humans are both sinusoidal, where the large part of blood flows through open-circulation routes with NP filtration at interendothelial cell slits [46] . The liver capillaries of mice, rats, pigs and humans are all sinusoidal with open fenestrae, but the average number of fenestrae per square micrometer in mice is lower than that of rats and humans (this number is 14, 20 and 20 in mice, rats and humans, respectively, but it is not available for pigs) [47] . Blood flows to some organs (e.g., liver, skin) are age-and species-dependent [48, 49] . Age difference in selected studies may thus be an important factor in our observed results. Immunologically, there are species differences in the plasma membrane receptor expression and functionality of macrophages [50] that may play a significant role in the NP opsonization, endocytosis and clearance. Physiologically, there are several parameters (e.g., liver weight fraction of body weight) that greatly affect NP pharmacokinetics, and rats and pigs are closer to humans than mice in these parameters [23] . The fact that the majority of NP-based drug formulations that are seemingly effective to decrease tumor sizes in mice, but are not effective in humans, further supports this supposition [51] . Overall, our finding is novel and it further questions the conventional wisdom of nanotoxicology evaluation solely using the mouse model. Nevertheless, at this stage, definitive conclusion cannot be made because there are differences in the AuNP used in different studies for model calibration, and strain differences within rodents could also play a role. While available data are very limited, the types of physiological and pharmacokinetic processes included in this model need to be taken into account whenever results seen in a rodent model are attempted to be extrapolated to humans. Additional comparative pharmacokinetic studies with rodents and pigs at similar ages using the same type of NP are needed to confirm these findings.
The above-mentioned fundamental anatomical, immunological and physiological differences between species are difficult to compensate for in a mathematical model because there is lack of sufficiently granular in vivo pharmacokinetic data in order to separate out the different mechanisms. Nevertheless, a computational framework built on PBPK modeling provides the most promising approach to integrate various mechanistic factors into whole body crossspecies predictive models. It has been demonstrated that PEGylation of AuNP is unstable in vivo due to the degradation of the polymer shell by proteolytic enzymes in the liver [52] . The effect of the unstability of PEGylation on AuNP pharmacokinetics is not mathematically evaluated due to the lack of timeintensive pharmacokinetic data for the same AuNP with and without PEGylation in more than two species. Another issue is that particle physicochemical properties, such as the state of agglomeration and surface charge, are not mathematically introduced into the model because there are not adequate data to simulate these factors. Once the aforementioned data are available, this present framework provides a computational platform to incorporate various factors to decipher the pharmacokinetic characteristics of NP.
To demonstrate model application in exposure and risk assessment, a comprehensive literature review on the AuNP toxicity was conducted (Supplementary Table 4) . In order to provide a conservative risk assessment, the lowest reported toxic concentrations of AuNP in rats [26] , human tissue [43] and blood cells [44] were selected. The associated human equivalent doses were calculated by using the optimal human model ( Figure 5 ). The congruence of these results suggests that our model provides a framework to integrate in vitro and in vivo toxicity studies to inform NP exposure and risk assessment. These results are informative for the design of human clinical trials.
Of note, this framework can be used to correlate NP in vitro cellular uptake to in vivo pharmacokinet- [39] (symbols) versus predicted (lines) blood concentrations of gold nanoparticles after intravenous injection (0.005857 mg/kg) using human models derived from different animal models. Animal-to-human extrapolation was conducted by changing the physiological parameters to be human-specific and keeping the endocytic and other nanoparticle-specific parameters the same as in the original animal models. Interspecies physiologically based pharmacokinetic modeling of gold nanoparticles Research Article ics, thus raising a possibility of developing NP PBPK models using alternative approaches. To be more specific, for all NP-specific parameters among different models in this framework, the distribution and permeability parameters are the same across models, but the endocytic parameters are model-specific. Thus, NP PBPK models may be created based on the present model framework and using species-and dose-specific endocytic parameters measured in vitro. Currently, there are a number of in vitro studies investigating cellular uptake of various NP, including AuNP, but most of these studies focus on uptake mechanisms and NP's fate after cellular internalization [6] . The experimental designs of available studies make it difficult to conduct IVIVE. To address this significant data gap, the present model was designed to include in vitro cellular uptake kinetic parameters. The following suggestions need to be considered in designing future cellular uptake studies. First, cell models should include the type of cells in which NP mainly accumulate in vivo, such as Kupffer cells and spleen/ lung macrophages which are the rate-limiting factors in systemic NP biodistribution. Wherever possible the primary cell type should be used rather than an immortalize cell line. A time-dependent study should also be conducted to identify the optimal incubation time when the uptake rate is at the maximum prior to a concentration-dependent study to determine the uptake kinetics. Data should be expressed in the unit of 'ng/h/cell,' so that the data can be converted to 'μg/h' for a particular tissue. Next, an appropriate mathematical equation (e.g., the Hill function) should be used to fit the concentration-dependent uptake kinetic data, in which related kinetic parameters can be calculated and incorporated into the present PBPK model. In addition to the in vitro cellular uptake studies, in vitro toxicity studies using the same human cells, in vivo toxicity studies with rats at <0.01 mg/kg doses and mechanistic pharmacokinetic modeling studies taking into account species differences in physiology and anatomy are warranted. Finally, this model based on PEG-coated AuNP does not take into account species differences in protein corona formation which could further impact PBPK model structure and interspecies extrapolations [9] . An approach to deal with timescale differences in protein corona formation in non-PEGylated NP has been addressed [9] . All of these proposed suggestions should be incorporated into the present computational framework to improve the risk assessment of AuNP. Blue and red lines represent model-predicted maximum concentrations of gold nanoparticles in the liver and blood, respectively, of humans after intravenous injection (0.001-100 mg/kg). The dashed arrows point to concentrations of gold nanoparticles where in vitro cytotoxicity (13 μg/ml) or hemolysis (50 μg/ml) was observed in primary human dermal fibroblasts [43] and blood cells [44] or where liver toxicity (0.01 mg/kg) was observed in rats [26] . Reference citations are given in square brackets. The solid arrows point to the model-predicted human equivalent dose (HED) associated with the reported in vitro cytotoxicity (HED = 1 mg/kg), hemolysis (HED = 5 mg/kg) and in vivo toxicity (HED = 0.005 mg/kg). Increased apoptotic rate by 23-44% after 72 h exposure in primary human dermal fibroblasts [43] Changes on the expression of genes related to detoxification and lipid metabolism in liver [26] ~5 0% hemolysis after 24 h exposure [44] Simulated maximum concentration (µg/g) Dose (mg/kg) Blood Liver future science group Research Article Lin, Monteiro-Riviere, Kannan & Riviere titative research avenue toward predictive nanotoxicity assessment, safety evaluation of NP-based drug formulations and NP interspecies pharmacokinetic extrapolation.
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• Interspecies and in vitro to in vivo extrapolations of pharmacokinetic and toxicology data are crucial for successful translation from laboratory studies to humans and for proper risk assessment of nanomaterials.
• We developed a comprehensive computational framework built on physiologically based pharmacokinetic modeling that successfully simulated tissue distribution of gold nanoparticles across a wide dose range and several species, including mice, rats and pigs.
• Animal-to-human extrapolation of nanomaterial pharmacokinetics was performed from mice, rats and pigs, respectively, to humans. • Rats and pigs seem to be more appropriate models than mice in species extrapolation of nanomaterial pharmacokinetics to humans and that the dose and age should be considered.
• Our results provide a scientific basis for researchers to select the most appropriate animal model and dosing paradigm for conducting future nanomaterial studies to increase the research relevance to humans. • Our model can be used to incorporate in vitro and in vivo cellular uptake and toxicity data to improve risk assessment of nanomaterials.
• This simulation approach may be applied to other types of nanomaterials and provides guidance to the design of future pharmacokinetic, toxicological and translational studies of nanomaterials. No writing assistance was utilized in the production of this manuscript.
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